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ABSTRACT 
Background. Staphylococcus aureus is the most common cause of endovascular infections. The 
staphylococcal accessory regulator A, sarA, is a major virulence determinant that may potentially 
impact MRSA persistence in such infections via its influence upon biofilm formation.  
 
Methods. Two healthcare-associated MRSA isolates from patients with persistent bacteremia 
and two prototypical community-acquired MRSA strains, and their respective isogenic sarA 
mutants were studied for in vitro: i) biofilm formation; ii) fibronectin-binding capacity;             
iii) autolysis; and iv) protease and nuclease activities. These assays were done in the presence or 
absence of sub-MIC vancomycin. In addition, these strain-pairs were compared for intrinsic 
virulence and responses to vancomycin therapy in experimental infective endocarditis (IE), a 
prototypical biofilm model. 
 
Results. All sarA mutants displayed significantly reduced biofilm formation and binding to 
fibronectin, but increased protease production in vitro vs. their respective parental strains. 
Interestingly, sub-MIC exposure to vancomycin significantly promoted biofilm formation and 
fibronectin-binding in parental strains, but not in sarA mutants. In addition, all sarA mutants 
became exquisitely sensitive to vancomycin therapy vs. their respective parental strains in the IE 
model. 
 
Conclusions. These observations suggest that sarA activation is important in persistent MRSA 
endovascular infection, potentially in the setting of biofilm formation.  
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
3 
INTRODUCTION 
 
Staphylococcus aureus is the most common cause of endovascular infections, including 
infective endocarditis (IE) syndromes which are associated with high morbidity and mortality 
[1]. The increase in prevalence of methicillin-resistant S. aureus (MRSA) strains in such 
infections, and the relatively high rates of vancomycin clinical failures in these synd omes 
caused by MRSA strains whose MICs fall within the susceptible range (MICs ≤ 2 g/ml) have 
further complicated the management of these patients [2]. In addition, MRSA is a predominant 
cause of healthcare-associated (HA) infections [3]. However, life-threatening infections caused 
by community-acquired (CA)-MRSA in otherwise healthy people outside of health care settings 
have recently reached epidemic proportions globally [4].  
 
The pathogenesis of S. aureus is complex and involves the coordinate expression of 
multiple gene products including surface adhesins, exoproteins and toxins. Of note, many 
staphylococcal virulence factors are controlled by a major regulatory locus called staphylococcal 
accessory regulator A, sarA [5]. The sarA locus consists of three overlapping transcripts, driven 
by three distinct promoters: P1, P3 and P2. These DNA-binding proteins bind to AT-rich 
inverted repeat or palindromic sequences on respective target promoters to control the expression 
of multiple genes [5]. Importantly, laboratory-derived sarA mutants have exhibited diminished 
virulence in infection models, including IE, osteomyelitis and arthritis [6, 7].  
 
Biofilm formation plays a critical role in the development of MRSA endovascular 
infections [8]. Treatment of these infections has become challenging since organisms within the 
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biofilm are significantly more resistant to antimicrobial agents, as well as to clearance by the 
host defense system [9]. In addition, recent studies suggest that sub-lethal doses of selected 
antibiotics (e.g., vancomycin) can induce biofilm formation in MRSA strains [10]. In this regard, 
SarA is an important positive regulator of biofilm development, in part due to its repressive 
activity on protease production [11-13]. For the first time to our knowledge, the current study 
examines the impact of vancomycin on sarA-mediated biofilm formation in MRSA in vitro, as 
well as in vivo in terms of intrinsic virulence and treatment outcomes in endovascular infections.  
 
MATERIALS AND METHODS  
 
MRSA Strains. Two HA-MRSA isolates, selected from a multi-national clinical trial, were from 
patients demonstrating  14 days of positive MRSA blood cultures despite receiving antibiotics 
to which the isolates were susceptible in vitro (Table 1) [14, 15]. In addition, two prototypical 
CA-MRSA strains, MW2 (USA400, reported to cause fatal infections in children [16]) and JE2 
(LAC, USA300 derivative that was cured of its three plasmids, obtained from NARSA [Network 
on Antimicrobial Resistance in Staphylococcus aureus]) were also chosen for this study. A site-
specific mutant was obtained by transducing the sarA::Tn917LTV1 mutation from strain 
ALC637 (Newman, sarA:Tn917LTV1) [17] into strain 324-136 using phage 80α 
(erythromycinr). A sarA deletion in strains JE2 and 300-169 was achieved by transducing the 
sarA::kan mutation from ALC2543 (COL with a sarA::kan mutation) [18] using phage 85 
(kanamycinr). The study MRSA strains were routinely grown in tryptic soy broth (TSB) or on TS 
agar (TSA). 
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Minimum inhibitory concentration (MIC) determination. MICs for vancomycin were 
determined by standard broth microdilution method as recommended by the Clinical and 
Laboratory Standards Institute [19].  
 
In vitro time-kill curve of vancomycin. The bactericidal activities of vancomycin (range, 1- to -
5x MICs) were compared between the parental strains and their respective sarA mutants by use 
of  killing curve analyses [20].  
 
Population analyses assay. Vancomycin population analyses were performed by standard 
protocols [21]. The range of vancomycin concentrations tested was 0.125 to 16 g/ml to 
encompass sublethal-to-lethal drug levels using an initial inoculum of ~109 CFU/ml. Population 
analysis curves were compared between each strain-pair [8]. 
 
Biofilm formation. Biofilm formation of the study MRSA strains was performed under static 
conditions [8, 22]. Briefly, MRSA cells from fresh culture plates were adjusted to a density of 
0.5 McFarland standard, and diluted 1:100 into brain heart infusion (BHI) supplemented with 
0.5% glucose; 200 μl of this suspension was transferred to 96-well tissue culture plates and 
incubated for 18 h at 37°C. After incubation, the wells were washed, air dried, stained with 
Safranin (0.1% in distilled water). The adhering dye was dissolved in 30% acetic acid, and 
absorption was measured at OD490nm to quantify biofilm formation [8, 22].  
 
Numerous investigations have shown that sub-MIC levels of some antibiotics can induce 
bacterial biofilm formation [8, 10, 23].  In this regard, we have recently reported that sub-MIC 
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vancomycin exposure can promote MRSA biofilm formation, a process that may have clinical 
significance [8]. Therefore, the above static biofilm formation assay was performed in parallel 
with exposure of 0.5x MIC of vancomycin.  
 
Biofilm stability. Bacterial biofilms consist of carbohydrates, proteins and extracellular DNA 
(eDNA) in variable proportions [9, 22]. Distinct biofilm chemical compositions are felt to 
contribute functionally and structurally to the organization of biofilm [9]. Therefore, differences 
in the stability of MRSA biofilm as a function of specific biochemical components were 
separately assessed in the presence of carbohydrate, protein, or DNA dispersal agents [22].  The 
supernatants of 18h-old biofilms generated by the study MRSA strains were replaced by fresh 
medium supplemented with either: i) 10 mM sodium metaperiodate; ii) 100 μg/ml proteinase K; 
or iii) 140 U/ml RNase-free DNase I to assess relative carbohydrate, protein and DNA content, 
respectively [22]. All incubations were for 2h at 37°C. Media without the above supplements 
served as respective controls. After treatment, the biofilms were quantified as described above.  
 
Autolysis assay. Standard Triton X-100-induced autolysis was performed as described [18]. In 
addition, it has been reported that increased staphylococcal autolysis mediated by sub-MIC 
vancomycin exposure can augment biofilm formation [10]. Thus, the MRSA strains were also 
examined for vancomycin-induced lysis. In brief, overnight cultured strains were adjusted to an 
OD580nm of 0.7, washed, exposed to 50 mM Tris-HCl (pH 7.2) containing either 0.05% Triton X-
100 or 0.5x MIC of vancomycin, and incubated at 30°C with agitation (200 rpm). Staphylococcal 
lysis was measured during 24 h incubation by determining the changes in OD580nm.  
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Adherence to fibronectin. For these assays, six-well tissue culture plates were coated with 
purified human fibronectin (50 μg/ml) for 18 h, then treated with 3% bovine serum albumin for 3 
h to prevent nonspecific adhesion [24]. Overnight cultured MRSA cells grown in the presence 
and absence of 0.5x MIC vancomycin were added to the plates (5x 103 CFU) and incubated for 1 
h [24]. Wells were then washed, and TSA were added to each well, incubated at 37oC for 
overnight. Adherence was expressed as the percentage (± SD) of the initial inoculum bound.  
Protease and nuclease activity. MRSA extracellular proteases and nucleases are essential 
modulators of biofilms, being involved in the degradation of the biofilm matrix; they may also 
play a critical role in the biofilm-deficient phenotype in the sarA mutants [9, 25, 26]. Therefore, 
we tested overall extracellular protease and nuclease production of the study strains using         
1% caseinate agar (for proteolysis activity) and DNase agar (for nuclease activity) plates in the 
presence or absence of 0.5x MIC of vancomycin [26, 27].  
 
Rabbit model of MRSA Infective endocarditis (IE). A well-characterized rabbit model of 
catheter-induced aortic valve IE with intravenous (iv) injection of ~105 CFU of each MRSA 
strain was used [15]. Rabbits were maintained in accordance with the American Association for 
Accreditation of Laboratory Animal Care criteria. The Animal Research Committee (IACUC) of 
the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center approved all 
animal study protocols. At 24 h after infection, animals were randomized to receive: i) no 
therapy [controls]; or ii) vancomycin at 15 mg/kg or 7.5 mg/kg, iv twice daily for three days for 
HA- and CA-MRSA strain sets, respectively. At 24 h after the last vancomycin dose, animals 
were sacrificed, and their cardiac vegetations, kidneys, and spleen were removed and 
quantitatively cultured [15]. MRSA counts in target tissue are given as the mean log10 CFU/g of 
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tissue (± SD). 
 
Assessment of sarA transcriptions in vitro and within cardiac vegetations in vivo by 
quantitative real-time PCR (qRT-PCR).  For sarA transcriptions in vitro, RNA was isolated 
from cultures that were grown for 24 h with/without 0.5x MIC of VAN exposure in order to 
compare to data generated in vivo within cardiac vegetation samples collected 24 h post-infection 
(see below) [15]. Briefly, two micrograms of DNase-treated RNA was transcribed into cDNA 
[15]. qRT-PCR was carried out using an ABI Prism 7000 instrument (Applied Biosystems) and 
the SYBR green PCR master kit (Applied Biosystems).  The primers used to amplify sarA were 
qRT-sarA-F (5’-TCTTGTTAATGCACAACAACGTAA-3’) and qRT-sarA-R                                                       
(5’-TGTTTGCTTCAGTGATTCGTTT-3’). gyrB was used to normalize for transcript 
quantification [15]. Relative quantification was calculated by the CT method [28]. PCR 
experiments were performed using two biological replicates, each tested in triplicate.  
 
For quantifying sarA transcripts within car iac vegetations, catheterized animals were infected 
with each parental strain as described above. At 24 h post-infection, animals were randomized to 
receive: i) no therapy; or ii) vancomycin as described above. Vancomycin was given for one day 
only (to assure adequate numbers of MRSA cells within cardiac vegetations for RNA 
extractions). At 24 h after the last vancomycin dose, animals were sacrificed, and their cardiac 
vegetations were quick-frozen in liquid nitrogen. Total RNA was isolated using Tri reagent 
(Ambion) according to the manufacturer's instructions, including a ¼-in. ceramic sphere in the 
cell disruption step [15]. Samples were then processed as described above. Quantitative RT-PCR 
analysis for sarA expression was performed on at least three different animals for each group. 
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RESULTS 
 
Vancomycin MICs.  
Vancomycin MICs were 0.5 g/ml for the two HA-MRSA strains, and 1.0 and 2.0 g/ml for 
CA-MRSA strains, MW2 and JE2, respectively. In addition, no differences were detected in 
vancomycin MICs between the parental and their respective sarA mutant strains.  
 
In vitro time-kill curve of vancomycin.  
The results of in vitro time-kill curve of vancomycin are shown in Fig. 1. No significant 
differences in vancomycin bactericidal effects were observed between parental and sarA mutant 
strains. In addition, no strains exhibited in vitro tolerance to vancomycin at 5x MIC exposure 
levels (Fig. 1).   
 
Population analyses. None of the study isolates revealed vancomycin hetero-resistant 
subpopulations (hVISA; data not shown). In addition, there were no population curve shifts in 
comparing the parent and sarA mutant strains within each strain-pair.  
 
Biofilm formation under static conditions. Consistent with previous reports [11, 12], all four 
sarA mutation were defective in biofilm formation as compared to their respective parental 
strains (Fig. 2A). Interestingly, sub-lethal (0.5x) MIC levels of vancomycin significantly 
promoted biofilm formation in both HA-MRSA parental strains and in the CA-MRSA parental 
strain, JE2 as compared to their respective parental controls without vancomycin exposure (Fig. 
2B). However, vancomycin exposure did not significantly change the biofilm formation profile 
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in the MW2 parental strain (Fig. 2B). Importantly, sub-lethal vancomycin exposure did not 
induce biofilm formation in any of the sarA mutants.  
 
Biofilm stability. Treatment with sodium metaperiodate, proteinase K or DNase I led to a 
similar significant reduction of biofilm formation in the two HA-MRSA parental strains as 
compared to respective controls without exposure to any dispersal agent (Supplementary          
Fig. S1). However, treatment with sodium metaperiodate did not cause a significant reduction of 
biofilm formation in two CA-MRSA parental strains vs. their respective controls without sodium 
metaperiodate exposure, suggesting that biofilm formed by these CA-MRSA strains might have 
relatively lower carbohydrate content (vs. protein and DNA; Fig. S1). For all the sarA mutants, 
treatment with sodium metaperiodate had little effect on the biofilm stability, whereas there was 
significant biofilm dispersion by treatment with proteinase K and DNase in two of the four sarA 
mutants, suggesting these two sarA mutant strains have less carbohydrate content as compared 
with protein and DNA content (Fig. S1).  
 
Cell Autolysis. No differences in autolysis profiles were observed between parental and sarA 
mutant strains in the presence of either Triton X-100 or 0.5x MIC vancomycin (data not shown).  
 
Adherence to fibronectin: As anticipated from prior studies [24, 29], inactivation of sarA led to 
significantly reduced fibronectin binding vs. their respective parental strain (p < 0.05, Fig. 3A). 
Interestingly, in the presence of 0.5x MIC vancomycin, two HA-MRSA parental strains showed 
significantly increased binding to fibronectin vs. their respective controls, whereas the two CA-
MRSA strains exhibited decreased fibronectin binding (although this did not reach statistical 
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significance) (Fig. 3B). For all the sarA mutants, fibronectin binding did not increase with 
vancomycin exposure (Fig. 3B). 
 
Protease and nuclease activity.  In accordance with previous studies showing that sarA 
negatively regulates protease and nuclease gene expression [12], the sarA mutants demonstrated 
increases in proteases and nuclease activity in all study strains, except for strain JE2 (in which 
nuclease activity did not change; Fig. 4). Of note, although sub-MIC levels of vancomycin had a 
positive impact on biofilm formation as documented above, there were no differences in either 
protease or nuclease production induced by vancomycin (Fig. 4).  
 
Experimental infective endocarditis (IE). At the 105 CFU challenge inoculum, three of the four 
sarA mutants (excluding JE2) exhibited reduced virulence as compared to their parental strains in 
terms of MRSA densities achieved within cardiac vegetations (but not kidneys or spleen;                 
p < 0.05, Fig. 5). Of note, vancomycin treatment resulted in dramatic and significant reductions 
of MRSA counts in all target tissues in animals infected with the sarA mutant strains                          
(3.8-6.6 log10 CFU/g. tissue reduction; p < 0.0005 vs. untreated sarA mutant controls; Fig. 5).          
In addition, vancomycin treatment resulted in ~80% culture-negativity in all target tissues in 
animals infected with sarA mutants in 300-169 and 324-136 strain backgrounds; also 18% and 
100% of organ cultures were sterile in animals infected with sarA mutant in MW2 and JE2 
backgrounds; respectively. In contrast, rabbits infected with three of the four parental strains (two 
HA-MRSA and MW2, but not JE2) did not respond to vancomycin treatment, with residual target 
tissue MRSA densities in vancomycin-treated animals being similar to those in their respective 
untreated control groups (Fig. 5).  
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sarA transcriptions in vitro and within cardiac vegetations. With 0.5x MIC VAN exposure          
in vitro, all parental strains exhibited significantly higher sarA transcript levels than their 
respective controls in the absence of VAN exposure (Fig. 6A). For sarA expression within 
cardiac vegetations, higher sarA expression profiles were observed in the VAN treatment groups 
vs. their respective controls without VAN therapy (Fig. 6B). Interestingly, higher sarA expression 
was detected in HA-MRSA vs. CA-MRSA parental strains without VAN treatment. However, 
these differences did not reach statistic significance (Fig. 6B). 
 
DISCUSSION 
Biofilm formation is considered to be a major virulence factor in many S. aureus 
syndromes, including IE [9, 25]. Biofilm formation not only facilitates bacterial colonization of 
host tissues, but also fosters resistance to bacterial clearance mediated by antimicrobial agents 
and by host immune responses [9, 25]. In addition, biofilms can serve as chronic foci of infection 
for metastatic spread of bacteria and release of toxins into the bloodstream, resulting in 
significant morbidity and mortality [9]. Therefore, biofilm formation has become a key target for 
the development of novel therapeutic tools against these life-threatening infections. In this study, 
we investigated the modulation of a central regulatory element that controls the production of 
many S. aureus virulence factors (including biofilm), sarA, as means of enhancing antimicrobial 
efficacy in a prototypical MRSA biofilm infection model (IE).  
 
In the current investigation, consistent with other reports, we observed that sarA mutants 
formed significantly less biofilm in vitro in all study strains as compared to their respective 
parental strains [11, 12]. It is well-known that sarA has a global effect on many S.aureus 
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virulence genes that seem to play a role in biofilm formation (e.g., multiple extracellular 
proteases, nuclease and fibronectin-binding proteins [FnBPs]) [30]. For instance, recent studies 
and our own current data show that the overall production of extracellular proteases is increased 
in sarA mutants, which may contribute to the reduced biofilm phenotype in such strains [26, 31, 
32]. In addition, there is growing evidence that the release of eDNA from bacterial cells 
undergoing autolysis during programmed cell death contributes to biofilm development [33, 34]. 
Therefore, an increased production of extracellular nuclease may contribute to the biofilm-
deficient phenotype of sarA mutants [34, 35]. Moreover, nuclease (nuc) mutants form a very 
thick biofilm containing increased levels of matrix-associated eDNA [33]. In this regard, in the 
current study, three of our four sarA mutants exhibited increased extracellular nuclease 
production, again correlating with reduced biofilm formation. Taken together, these results 
suggest that the regulatory role of sarA in repressing the production of extracellular enzymes 
(including proteases and nucleases) is one key factor leading to biofilm formation and stability 
[26].  
 
S. aureus biofilm matrices consist of proteins, DNA, and polysaccharide (also called the 
polysaccharide intercellular adhesion [PIA] or poly-N-acetylglucosamine [PNAG] material) [9, 
22]. Recently, it has become evident that the presence of PIA is not essential for biofilm 
development in many MRSA strains [29]. Interestingly, in these PIA-independent biofilms, 
FnBPs appear to “substitute” for PIA in driving biofilm formation [29]. In addition, this FnBP-
mediated biofilm seems to be particularly frequent among highly virulent MRSA isolates, 
suggesting the importance of PIA-independent biofilm formation in such strains [29]. SarA is a 
positive regulator of FnBP production and subsequent biofilm formation in two complementary 
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ways: i) by enhancement of fnb gene expression; and ii) by repression of extracellular proteases 
which normally cleave and remodel surface adhesins such as FnBP [12, 13]. Thus, we tested the 
fibronectin-binding capacities of our study strains. Our results, in agreement with other studies 
[24, 36], found that all sarA mutants had significantly decreased capacity to bind to fibronectin. 
This reduced fibronectin-binding phenotype was correlated with increased protease production 
observed in sarA mutants, ostensibly contributing to reduced bacterial colonization at the early 
steps of endovascular infection.   
Several groups have shown that sub-MIC levels of selected antibiotics, including 
vancomycin, can promote S. aureus biofilm formation in vitro [10, 37, 38]. In the current studies, 
we applied this concept to characterize the impact of sub-MIC levels of vancomycin on sarA-
mediated biofilm formation in a persistent endovascular infection model due to HA- and        
CA-MRSA strains. Vancomycin was chosen in this investigation because it remains a clinical 
mainstay as an anti-MRSA agent. We confirmed that sub-MIC vancomycin significantly 
promoted biofilm formation in three of four MRSA parental strains (excluding MW2).  In 
contrast, all sarA mutants demonstrated reduced biofilm formation in the presence or absence of 
sub-MIC vancomycin in vitro. In addition, we demonstrated that sub-MIC vancomycin exposure 
significantly increased sarA gene expression in all study parental strains studied in vitro vsersus 
their respective controls without vancomycin exposure. This outcome was mirrored in vivo, as 
vancomycin treatment resulted a trend towards higher MRSA sarA expression within IE cardiac 
vegetations vs. respective controls without vancomycin therapy. These phenotypic and genotypic 
differences in the impact of sub-MIC vancomycin on biofilm formation and sarA expression 
paralleled in vivo outcomes. Thus, animals infected with parental MRSA strains were resistant to 
vancomycin treatment, while animals infected with sarA mutants were exquisitely susceptible to 
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vancomycin therapy in the IE model.  
 
We recognize that additional mechanisms likely contribute to the differences in 
vancomycin-associated outcomes in vivo as noted above. For example, vancomycin has limited 
and slow penetration into biofilms [39, 40]. Therefore, one intriguing possibility is that sarA 
mutant strains form significantly thinner and/or less well-structured biofilms in vivo as compared 
to their respective parental strains. In turn, this latter phenotype may conceivably allow greater 
penetration of vancomycin into such defective biofilms. Further, Hsu et al. [10] reported that 
sub-lethal doses of vancomycin can induce more robust biofilm formation through an enhanced 
autolysis- and eDNA-dependent release in S. aureus. In contrast to their findings, however, the 
present studies were unable to detect any impact of sub-MIC vancomycin on either autolysis or 
nuclease or protease production, suggesting these latter mechanisms were not in-play in the 
current study strains.  
 
Lastly, we noted that mutations in sarA had a definable, albeit modest effect on innate 
MRSA virulence, being observed only with in cardiac vegetations. This impact of sarA on IE 
pathogenesis has been seen in prior studies in this model using other S. aureus strains [6, 24, 41]. 
Of major importance, vancomycin therapy in the experimental IE model was able to divulge the 
ability of sarA to blunt antimicrobial efficacies, presumably via a biofilm-dependent pathway. 
Interestingly, these in vivo results were observed despite similar vancomycin MICs and in vitro 
vancomycin killing kinetics between sarA mutants and their respective parental strains. These 
results suggest that sarA plays a key role in endovascular infections, especially in terms of 
antimicrobial therapy responsiveness, likely, at least in part, due to the decreased production of 
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extracellular protease, resulting in augmented biofilm formation. 
 
 In summary, for the first time in our knowledge, the present results reveal the importance 
of sarA in two critical aspects of S. aureus pathogenesis in endovascular infections caused by 
clinical isolates: biofilm formation and target tissue persistence. Although the mechanism(s) of 
these phenomena are not entirely defined, these data support the notion that suppression of SarA 
has therapeutic potential in the important context of biofilm-associated infections due to HA- and 
CA-MRSA. 
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TABLES 
 
Table 1.  S. aureus strains used in this study 
Strains Relevant characteristics Reference 
ALC637 Newman sarA:Tn917LTV1, ermR [17] 
ALC2543 COL sarA::kan [18] 
300-169 HA-MRSA (persistent bacteremia patient) [15] 
300-169 sarA 300-169 sarA::kan This study 
324-136 HA-MRSA (persistent bacteremia patient) [15] 
324-136 sarA 324-136 sarA::Tn917LTV1 This study 
MW2 CA-MRSA, USA 400 [18] 
ALC5415 MW2 sarA::kan [18] 
JE2 CA-MRSA, LAC, USA 300 [42] 
JE2 sarA JE2 sarA::kan This study 
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FIGURE LEGEND 
 
Figure 1.  In vitro time-kill curves of vancomycin against HA-MRSA (Panel A: 300-169 and 
324-136) and CA-MRSA (Panel B: MW2 and JE2) strain sets. ■, Control; ◇, 1x MIC of 
vancomycin; △, 2x MIC of vancomycin;,5x MIC of vancomycin. 
 
Figure 2. Impact of sarA on biofilm formation. Panel A, biofilm formation of the wild types and 
their isogenic sarA mutants was quantified using a microtitler plate assay by solubilizing the 
safranin in 30% acetic acid and absorption was measured at 490nm. Results are shown as the 
mean of the A490nm ± SD from three independent experiments, each of which was done in 
triplicate. *P<0.005; **P<0.0005 the sarA mutants vs. their respective parental strain. Panel B, 
effect of 0.5x MIC of vancomycin (VAN) treatment on biofilm formation. Biofilm formation 
without VAN exposure was defined as being A490nm 1.0, and represented by the dashed line.       
■, parental; □, sarA mutant; * P < 0.05 vs. control without VAN exposure.  
 
Figure 3. Adherence of the study MRSA strain sets to immobilized human fibronectin in the 
absence (Panel A) and presence (Panel B) of 0.5x MIC vancomycin (VAN). Controls without 
VAN exposure set up 100% adherence to fibronectin (panel B). ■, parental; □, sarA mutant; * 
P < 0.05 vs. their respective parental strain (Panel A) or vs. controls without VAN exposure 
(Panel B).  
 
Figure 4. Production of extracellular protease and nuclease by the study strain sets in the 
absence and presence of 0.5x MIC vancomycin (VAN). Results were assessed after overnight 
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incubation of the study strains on caseinate and DNase agar plates for protease and nuclease, 
respectively. P: parental strain; S: sarA mutant strain. 
 
Figure 5. MRSA densities in target tissues in the IE model with and without vancomycin (VAN) 
treatment (15 mg/kg and 7.5 mg/kg iv, bid for 3 days for HA-MRSA and CA-MRSA strains, 
respectively). Panel A: HA-MRSA strain sets; and Panel B: CA-MRSA strain sets. Each dot 
represents one rabbit. Horizontal black bars indicate means of observations.  
 
Figure 6. Expression of sarA in all study MRSA parental strain with/without 0.5x MIC VAN 
exposure at 24 h in vitro (A) and within infected cardiac vegetations with/without VAN therapy 
in the IE model at 24 h post-infection (B) by qRT-PCR. Relative transcript levels of sarA 
represent the mean (+ SD) of two biological replicates in vitro and of at least three animals per 
group in vivo (fold changes versus gyrB). * indicates P < 0.05; and ** indicates P < 0.005 
compared with their respective controls without VAN exposure in vitro. 
 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
20 
REFERENCES 
 
1. Fowler VG, Jr., Justice A, Moore C, et al. Risk factors for hematogenous complications of 
intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 
40:695-703. 
2. Rubinstein E. Staphylococcus aureus bacteraemia with known sources. Int J of Antimicrob 
Agents 2008; 32 Suppl 1:S18-20. 
3. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of 
meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85. 
4. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J 
Med 2005; 352:1485-7. 
5. Cheung AL, Nishina KA, Trotonda MP, Tamber S. The SarA protein family of 
Staphylococcus aureus. Int J Biochem Cell Bio 2008; 40:355-61. 
6. Xiong YQ, Willard J, Yeaman MR, Cheung AL, Bayer AS. Regulation of Staphylococcus 
aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental 
infective endocarditis. J Infect Dis 2006; 194:1267-75. 
7. Blevins JS, Elasri MO, Allmendinger SD, et al. Role of sarA in the pathogenesis of 
Staphylococcus aureus musculoskeletal infection. Infect Immun 2003; 71:516-23. 
8. Abdelhady W, Bayer AS, Seidl K, et al. Reduced vancomycin susceptibility in an in vitro 
catheter-related biofilm model correlates with poor therapeutic outcomes in experimental 
endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial Agents 
Chemother 2013; 57:1447-54. 
9. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immun 2008; 322:207-28. 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
21 
10. Hsu CY, Lin MH, Chen CC, et al. Vancomycin promotes the bacterial autolysis, release of 
extracellular DNA, and biofilm formation in vancomycin-non-susceptible Staphylococcus 
aureus. FEMS Immunol Med Microbiol 2011; 63:236-47. 
11. Trotonda MP, Manna AC, Cheung AL, Lasa I, Penades JR. SarA positively controls bap-
dependent biofilm formation in Staphylococcus aureus. J Bacteriol 2005; 187:5790-8. 
12. Mrak LN, Zielinska AK, Beenken KE, et al. saeRS and sarA Act Synergistically to Repress 
Protease Production and Promote Biofilm Formation in Staphylococcus aureus. PLoS One 2012; 
7:e38453. 
13. Zielinska AK, Beenken KE, Mrak LN, et al. sarA-mediated repression of protease production 
plays a key role in the pathogenesis of Staphylococcus aureus USA300 isolates. Mol Microbiol  
2012; 86:1183-96. 
14. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for 
bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65. 
15. Seidl K, Chen L, Bayer AS, Hady WA, Kreiswirth BN, Xiong YQ. Relationship of agr 
expression and function with virulence and vancomycin treatment outcomes in experimental 
endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 
2011; 55:5631-9. 
16. CDC. From the Centers for Disease Contol and Prevention. Four pediatric deaths from 
community-acquired methicillin-resistant Staphylococcus aureus, Minnesota and North Dakota, 
1997-1999. JAMA 1999; 282:1123-5  
17. Wolz C, Pohlmann-Dietze P, Steinhuber A, et al. Agr-independent regulation of fibronectin-
binding protein(s) by the regulatory locus sar in Staphylococcus aureus. Mol Microbiol 2000; 
36:230-43. 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
22 
18. Trotonda MP, Xiong YQ, Memmi G, Bayer AS, Cheung AL. Role of mgrA and sarA in 
methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active 
antibiotics. J Infect Dis 2009; 199:209-18. 
19. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically: approved standard. 6th ed NCCLS document M7-A6 Wayne, PA. 2003; 60:495-500. 
20. Xiong YQ, Hady WA, Deslandes A, et al. Efficacy of NZ2114, a novel plectasin-derived 
cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant 
Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55:5325-30. 
21. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus 
aureus infection with daptomycin are associated with alterations in surface charge, membrane 
phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008; 52:269-78. 
22. Seidl K, Bayer AS, Fowler VG, Jr., et al. Combinatorial phenotypic signatures distinguish 
persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. 
Antimicrob Agents Chemother 2011; 55:575-82. 
23. Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs 2011; 34:737-51. 
24. Xiong YQ, Bayer AS, Yeaman MR, Van Wamel W, Manna AC, Cheung AL. Impacts of 
sarA and agr in Staphylococcus aureus strain Newman on fibronectin-binding protein A gene 
expression and fibronectin adherence capacity in vitro and in experimental infective endocarditis. 
Infect Immun 2004; 72:1832-6. 
25. Boles BR, Thoendel M, Roth AJ, Horswill AR. Identification of genes involved in 
polysaccharide-independent Staphylococcus aureus biofilm formation. PLoS One 2010; 
5:e10146. 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
23 
26. Beenken KE, Mrak LN, Griffin LM, et al. Epistatic relationships between sarA and agr in 
Staphylococcus aureus biofilm formation. PLoS One 2010; 5:e10790. 
27. Seidl K, Bayer AS, McKinnell JA, Ellison S, Filler SG, Xiong YQ. In vitro endothelial cell 
damage is positively correlated with enhanced virulence and poor vancomycin responsiveness in 
experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Cell Microbiol 
2011; 13:1530-41. 
28. Montgomery CP, Boyle-Vavra S, Daum RS. Importance of the global regulators agr and 
saeRS in the pathogenesis of CA-MRSA USA300 infection. PLoS One 2010; 5:e15177. 
29. O'Neill E, Pozzi C, Houston P, et al. A novel Staphylococcus aureus biofilm phenotype 
mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol 2008; 190:3835-
50. 
30. Dunman PM, Murphy E, Haney S, et al. Transcription profiling-based identification of 
Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001; 183:7341-
53. 
31. Tsang LH, Cassat JE, Shaw LN, Beenken KE, Smeltzer MS. Factors contributing to the 
biofilm-deficient phenotype of Staphylococcus aureus sarA mutants. PLoS One 2008; 3:e3361. 
32. Cassat J, Dunman PM, Murphy E, et al. Transcriptional profiling of a Staphylococcus aureus 
clinical isolate and its isogenic agr and sarA mutants reveals global differences in comparison to 
the laboratory strain RN6390. Microbiol 2006; 152:3075-90. 
33. Mann EE, Rice KC, Boles BR, et al. Modulation of eDNA release and degradation affects 
Staphylococcus aureus biofilm maturation. PLoS One 2009; 4:e5822. 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
24 
34. Rice KC, Mann EE, Endres JL, et al. The cidA murein hydrolase regulator contributes to 
DNA release and biofilm development in Staphylococcus aureus. P Natl Acad Sci USA 2007; 
104:8113-8. 
35. Izano EA, Amarante MA, Kher WB, Kaplan JB. Differential roles of poly-N-
acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and 
Staphylococcus epidermidis biofilms. Appl Environ Microb 2008; 74:470-6. 
36. Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in 
endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin 
Invest 2003; 112:222-33. 
37. Mirani ZA, Jamil N. Effect of sub-lethal doses of vancomycin and oxacillin on biofilm 
formation by vancomycin intermediate resistant Staphylococcus aureus. J Basic Microb 2011; 
51:191-5. 
38. Kaplan JB, Izano EA, Gopal P, et al. Low levels of beta-lactam antibiotics induce 
extracellular DNA release and biofilm formation in Staphylococcus aureus. MBio 2012; 
3:e00198-12. 
39. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus 
and Staphylococcus epidermidis biofilms. J Antimicrob Chemother 2010; 65:1955-8. 
40. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of 
vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 
2005; 49:2467-73. 
41. van Wamel W, Xiong YQ, Bayer AS, Yeaman MR, Nast CC, Cheung AL. Regulation of 
Staphylococcus aureus type 5 capsular polysaccharides by agr and sarA in vitro and in an 
experimental endocarditis model. Microb Pathogenesis 2002; 33:73-9. 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
25 
42. Spentzas T, Kudumula R, Acuna C, et al. Role of bacterial components in macrophage 
activation by the LAC and MW2 strains of community-associated, methicillin-resistant 
Staphylococcus aureus. Cell Immunol 2011; 269:46-53. 
 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
26 
 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
27 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
28 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
29 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
30 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
31 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
32 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
33 
 
 at Zentralbibliothek on February 13, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
